Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Nov;51(11):1100–1104. doi: 10.1136/thx.51.11.1100

Salmeterol tachyphylaxis in steroid treated asthmatic subjects.

H Booth 1, R Bish 1, J Walters 1, F Whitehead 1, E H Walters 1
PMCID: PMC1090520  PMID: 8958892

Abstract

BACKGROUND: Tachyphylaxis to the protection afforded by salmeterol to broncho-constrictor stimuli after regular use has been described in patients with mild asthma not receiving inhaled corticosteroids. The present study was performed to investigate whether airway tachyphylaxis occurs in symptomatic asthmatic subjects receiving inhaled corticosteroids, the group for whom salmeterol is recommended in clinical practice. METHODS: Thirty one adult patients with symptomatic chronic asthma who were receiving inhaled corticosteroids were randomised in a double blind manner and on a 2:1 basis to receive salmeterol 50 micrograms (n = 22) or placebo (n = 9) twice daily. Baseline forced expiratory volume in one second (FEV1) was measured during the run-in period, on day 0, and after four and eight weeks of regular treatment (following a 36 hour test drug washout period). Airway responsiveness to methacholine was measured one hour after administration of the test drug on these occasions. Diary cards were kept throughout the study and for a two week follow up period. RESULTS: Baseline FEV1 was not significantly different between the treatment groups or between visits. There was significant bronchodilatation one hour after salmeterol administration at 0, four, and eight weeks. No significant tachyphylaxis of the bronchodilator action of salmeterol was seen. Protection against methacholine induced bronchoconstriction reduced from 3.3 doubling dilutions after the first dose of salmeterol to two doubling dilutions after four and eight weeks of regular treatment. Symptom scores and "rescue" salbutamol use were significantly reduced during salmeterol treatment and daytime improvements were maintained into the follow up period. CONCLUSIONS: Inhaled corticosteroids did not prevent tachyphylaxis to the protection afforded by salmeterol to methacholine induced bronchoconstriction. The clinical significance, if any, of these findings remains to be defined.

Full text

PDF
1100

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Booth H., Fishwick K., Harkawat R., Devereux G., Hendrick D. J., Walters E. H. Changes in methacholine induced bronchoconstriction with the long acting beta 2 agonist salmeterol in mild to moderate asthmatic patients. Thorax. 1993 Nov;48(11):1121–1124. doi: 10.1136/thx.48.11.1121. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cheung D., Timmers M. C., Zwinderman A. H., Bel E. H., Dijkman J. H., Sterk P. J. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992 Oct 22;327(17):1198–1203. doi: 10.1056/NEJM199210223271703. [DOI] [PubMed] [Google Scholar]
  3. Cockcroft D. W., McParland C. P., Britto S. A., Swystun V. A., Rutherford B. C. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993 Oct 2;342(8875):833–837. doi: 10.1016/0140-6736(93)92695-p. [DOI] [PubMed] [Google Scholar]
  4. Greening A. P., Ind P. W., Northfield M., Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet. 1994 Jul 23;344(8917):219–224. doi: 10.1016/s0140-6736(94)92996-3. [DOI] [PubMed] [Google Scholar]
  5. Harvey J. E., Tattersfield A. E. Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects. Thorax. 1982 Apr;37(4):280–287. doi: 10.1136/thx.37.4.280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Holgate S. T., Baldwin C. J., Tattersfield A. E. beta-adrenergic agonist resistance in normal human airways. Lancet. 1977 Aug 20;2(8034):375–377. doi: 10.1016/s0140-6736(77)90304-x. [DOI] [PubMed] [Google Scholar]
  7. Lipworth B. J., Struthers A. D., McDevitt D. G. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989 Sep;140(3):586–592. doi: 10.1164/ajrccm/140.3.586. [DOI] [PubMed] [Google Scholar]
  8. Lundback B., Rawlinson D. W., Palmer J. B. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group. Thorax. 1993 Feb;48(2):148–153. doi: 10.1136/thx.48.2.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Newnham D. M., McDevitt D. G., Lipworth B. J. Bronchodilator subsensitivity after chronic dosing with eformoterol in patients with asthma. Am J Med. 1994 Jul;97(1):29–37. doi: 10.1016/0002-9343(94)90045-0. [DOI] [PubMed] [Google Scholar]
  10. O'Connor B. J., Aikman S. L., Barnes P. J. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med. 1992 Oct 22;327(17):1204–1208. doi: 10.1056/NEJM199210223271704. [DOI] [PubMed] [Google Scholar]
  11. Pearlman D. S., Chervinsky P., LaForce C., Seltzer J. M., Southern D. L., Kemp J. P., Dockhorn R. J., Grossman J., Liddle R. F., Yancey S. W. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992 Nov 12;327(20):1420–1425. doi: 10.1056/NEJM199211123272004. [DOI] [PubMed] [Google Scholar]
  12. Ramage L., Lipworth B. J., Ingram C. G., Cree I. A., Dhillon D. P. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994 May;88(5):363–368. doi: 10.1016/0954-6111(94)90042-6. [DOI] [PubMed] [Google Scholar]
  13. Reihsaus E., Innis M., MacIntyre N., Liggett S. B. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol. 1993 Mar;8(3):334–339. doi: 10.1165/ajrcmb/8.3.334. [DOI] [PubMed] [Google Scholar]
  14. Roberts J. M., Jacobs M. M., Cheng J. B., Barnes P. J., O'Brien A. T., Ballard P. J. Fetal pulmonary beta-adrenergic receptors: characterization in the human and in vitro modulation by glucocorticoids in the rabbit. Pediatr Pulmonol. 1985 May-Jun;1(3 Suppl):S69–S76. [PubMed] [Google Scholar]
  15. Solèr M., Joos L., Bolliger C. T., Elsasser S., Perruchoud A. P. Bronchoprotection by salmeterol: cell stabilization or functional antagonism? Comparative effects on histamine- and AMP-induced bronchoconstriction. Eur Respir J. 1994 Nov;7(11):1973–1977. [PubMed] [Google Scholar]
  16. Tashkin D. P., Conolly M. E., Deutsch R. I., Hui K. K., Littner M., Scarpace P., Abrass I. Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. Am Rev Respir Dis. 1982 Feb;125(2):185–193. doi: 10.1164/arrd.1982.125.2.185. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES